Jump to content
African American Forum
FORUMS BLOG/NEWS USER BLOGS USER MEDIA ADVERTS   ADD  MANAGE CHAT CLUBS & USER'S PERSONAL FORUMS LINK EXCHANGE

Damon Salvatore

Members
  • Content Count

    22
  • Joined

  • Last visited

Community Reputation

0 Neutral
  1. To order this detailed 640+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html Key Inclusions § A detailed assessment of the current market landscape of microbiome therapeutics, providing information on drug / therapy developer(s) (such as year of establishment, location of headquarters and company size), clinical study sponsor(s) or collaborators, phase of development (clinical, preclinical, and discovery stage) of product candidates, type of molecule (small molecule and biologic), type of therapy (prebiotic,
  2. The concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, defining a new frontier in the field of medicine. Despite having captured the interest of several venture capital firms and big pharma players, no microbiome-based therapeutic has been officially approved by an authorized medical product regulator. However, the current development pipeline of microbiome therapeutics has several promising candidates that are likely to result in commercial success stories soon. To order this 640+ page report, which features 235+ fig
  3. Roots Analysis has announced the addition of “Human Microbiome Market, 2019-2030” report to its list of offerings. To order this 640+ page report, which features 235+ figures and 275+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html Key Market Insights § Presently, 260 drug candidates are being evaluated in clinical / preclinical stages for the treatment of a wide variety of disease indications; the US has emerged as the major hub for microbiome-based research § The pipeline
  4. Over the years, extensive R&D efforts have enabled microbiome-based therapy / diagnostic developers to make significant strides, in terms of progressing proprietary product candidates into the clinic Roots Analysis has announced the addition of “Human Microbiome Market, 2019-2030” report to its list of offerings The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes: § A detailed assessment of the current market landscape of microbiome therapeutic
  5. Over the years, extensive R&D efforts have established the basis for a wide range of microbiome-based therapeutic and diagnostic products, which may cause a paradigm shift in the way healthcare is delivered in the foreseen future Roots Analysis has announced the addition of “Human Microbiome Market, 2019-2030” report to its list of offerings. The concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, defining a new frontier in the field of medicine. Despite having captured the interest of several venture
  6. To order this 300+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/oligonucleotide-synthesis/304.html Key Inclusions § A detailed review of the current status of the market with respect to oligonucleotide manufacturers focused on research and diagnostic, and therapeutic applications. It features information on the year of establishment, company size, scale of operation (preclinical, clinical, and commercial), location of headquarters, number of manufacturing facilities, along with their locations (country-wise), and regulatory accreditatio
  7. Several big pharma companies are known to outsource more than half of their clinical-stage oligonucleotide manufacturing operations. Anticipating a sharp rise in demand, oligonucleotide manufacturers are increasingly consolidating their portfolios, building new capabilities and expanding their respective capacities, mostly through acquisitions, in order to gain a competitive edge. To order this 300+ page report, which features 140+ figures and 190+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/oligonucleotide-synthesis/304.html The USD
  8. Roots Analysis has done a detailed study on “Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030.”” covering key aspects of the industry’s evolution and identifying potential future growth opportunities. To order this 300+ page report, which features 140+ figures and 190+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/oligonucleotide-synthesis/304.html Key Market Insights § More than 80 companies currently claim to offer manufacturing relate
  9. The applications of oligonucleotides are vast, even beyond the life science / pharma sector; however, owing to complexities associated with the synthesis and processing of these molecules, such operations are usually outsourced to capable CMOs Roots Analysis is pleased to announce the publication of its recent study, titled, “Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030.” The report features an extensive study of the current scenario and future potential of the custom syn
  10. To order this detailed 300+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html Key Inclusions § A detailed review of the overall landscape of companies offering contract services for the manufacturing of HPAPIs and cytotoxic drugs, along with information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, number and location of manufacturing facilities, facility size, type of service(s) offered (clinical manufacturing, com
  11. Development initiatives of HPAPIs and cytotoxic drugs are generally very demanding, both in terms of experience and capital investment. Most companies generally lack the necessary resources to meet the aforementioned requirements and are unable to set up dedicated HPAPI and cytotoxic drug manufacturing facilities. This has led to an increased demand for contract manufacturing service providers in this field. To order this 300+ page report, which features 75+ figures and 150+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-ma
  12. Roots Analysis has done a detailed study on “HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030”, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. To order this 300+ page report, which features 75+ figures and 150+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html Key Market Insights § Close to 120 companies across the globe claim to possess the required expertise and infrastructure to offer contract manufacturing serv
  13. Manufacturing highly potent drug products is technically and financially demanding; as a result, drug manufacturers are becoming increasingly reliant on contract service providers Roots Analysis is pleased to announce the publication of its recent study, titled, “HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030.” The report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of HPAPIs and cytotoxic drugs. The study also features a detailed analysis of the key drivers and trends re
  14. To order this detailed 300+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/patient-recruitment-and-retention-services-market-2019-2030/245.html Key Inclusions § A detailed assessment of the current market landscape, including information on drug developer(s), § A detailed assessment of the current market landscape of companies offering patient recruitment and retention services, including information on over 10 types of patient outreach methods employed, types of services offered ([A] patient recruitment (including pre-screening an
  15. A steadily increasing demand for study participants and the complexities associated with patient enrollment has imposed a significant burden on drug developer companies, prompting them to enlist the services of specialty service providers. Presently, close to 140 companies are actively offering patient recruitment and retention services. Majority of these players possess vast service portfolios and utilize diverse patient outreach methods to recruit study participants across different geographies and therapeutic indications. To order this 300+ page report, which features 90+ figure
×
  • Create New...